CCT129957

Cat. No.:	HY-111208
CAS No.:	883098-58-6
Molecular Formula:	$C_{17}H_{15}N_3O_3$
Molecular Weight:	309.32
Target:	Phospholipase
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (323.29 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.2329 mL	16.1645 mL	32.3290 mL
	5 mM	0.6466 mL	3.2329 mL	6.4658 mL
	10 mM	0.3233 mL	1.6164 mL	3.2329 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC_{50} of ~3 μM and a GC_{50} of 15 μM. CCT129957 inhibits Ca^{2+} release in squamous carcinoma cells at ~15 μM[1][2].

IC_{50} & Target

IC50: ~3 μM (Phospholipase C-γ (PLC-γ))[1]

In Vitro

The phenyl group on the left side sat in a lipophilic pocket formed of various amino acids. The predicted binding mode of CCT129957 displays a robust hydrogen bond pattern as well as a lipophilic contact[1].

CCT129957 inhibits the cell growth of renal UO-31 and the breast T-47D cancer cell lines by ~60-70%[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Reynisson J, et al. The identification of novel PLC-gamma inhibitors using virtual high throughput screening. Bioorg Med Chem. 2009 Apr 15;17(8):3169-76.

[2]. Feng L, et al. The effect of PLC-γ2 inhibitors on the growth of human tumour cells. Eur J Med Chem. 2012 Aug;54:463-9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA